Opportunity Information: Apply for APS OAA 13 000001
Apply for APS OAA 13 000001
- The Agency for International Development in the health sector is offering a public funding opportunity titled "APS for Microbicide Research, Development, and Introduction, Round 2" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 98.001 USAID Foreign Assistance for Programs Overseas.
- This funding opportunity was created on Feb 4, 2013 and posted on Feb 4, 2013.
- Applicants must submit their applications by Mar 18, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $168,000,000.00 in funding.
- Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The APS for Microbicide Research, Development, and Introduction, Round 2 (Funding Opportunity Number: APS OAA 13 000001) is a USAID discretionary funding opportunity that uses a cooperative agreement mechanism to support work that helps move HIV prevention microbicides from promising research results toward real-world availability and use. The opportunity builds directly on the CAPRISA 004 clinical trial of 1% tenofovir gel, a landmark study led by South African investigators and jointly supported by USAID and the Government of South Africa. When its results were announced in July 2010, the trial provided the first clear proof that a vaginal microbicide could significantly reduce the risk of HIV infection. That proof-of-concept milestone shifted the field from primarily asking whether microbicides could work to tackling the practical next steps required to make them safe, approved, and ready for introduction in settings where women face disproportionate HIV risk and often lack prevention options they can control.
The central theme of the announcement is that while ongoing research and development for improved and alternative microbicide products remains important, USAID is signaling a broader program direction that extends beyond early-stage R&D. In other words, the focus is not only on discovering or refining microbicide candidates, but also on the set of activities needed to confirm safety and effectiveness, navigate regulatory pathways with national authorities, and plan for implementation and introduction. This includes the kind of coordinated, multi-part work typically required to translate clinical trial outcomes into public health tools: additional studies to strengthen the evidence base, preparation of regulatory submissions and supporting documentation, and the practical groundwork for eventual rollout in developing-country contexts.
From a funding and administrative standpoint, the opportunity is listed under the Health funding activity category and is associated with CFDA 98.001 (USAID Foreign Assistance for Programs Overseas). It is open eligibility-wise to a wide range of applicants, described as unrestricted, meaning that any type of entity may apply as long as it meets any additional eligibility conditions described in the full announcement. Because the instrument is a cooperative agreement, applicants should expect substantial involvement by USAID during implementation compared with a standard grant, often reflecting the complexity of product-development and introduction work that requires close coordination with funders, implementing partners, regulators, and other stakeholders.
Financially, the opportunity includes an award ceiling of $168,000,000 and an award floor of $0, indicating a potentially large overall funding amount but with flexibility in individual award sizes depending on proposed activities and USAID priorities. Cost sharing or matching is required, so applicants would need to bring some portion of resources to the table, whether in cash or allowable in-kind contributions, consistent with USAID rules and the specific terms spelled out in the full solicitation.
The timeline in the posting shows it was posted on February 4, 2013, with an original and current closing date of March 18, 2013, and an archive date of April 17, 2013, meaning the opportunity is historical and no longer accepting applications. For questions tied to accessing the full announcement at the time, the listed point of contact was Kathleen Bumpass, Contracts Specialist, reachable by phone at 202-567-5008.
Frequently Asked Questions (FAQs)
What is this funding opportunity called and what is the funding opportunity number?
The opportunity is titled "APS for Microbicide Research, Development, and Introduction, Round 2" and the Funding Opportunity Number is APS OAA 13 000001.
Which U.S. government agency is offering this opportunity?
This is a USAID (U.S. Agency for International Development) discretionary funding opportunity.
What is the main purpose of this APS?
The APS supports work that helps move HIV prevention microbicides from promising research results toward real-world availability and use, including steps needed to confirm safety and effectiveness, navigate regulatory pathways, and plan for implementation and introduction.
What type of funding instrument is used?
The mechanism is a cooperative agreement.
How is a cooperative agreement different from a standard grant in this APS?
Because it is a cooperative agreement, applicants should expect substantial involvement by USAID during implementation compared with a standard grant, reflecting the complexity and coordination needs of product-development and introduction work.
What topic area or funding activity category does this opportunity fall under?
The opportunity is listed under the Health funding activity category.
What CFDA number is associated with this opportunity?
The opportunity is associated with CFDA 98.001 (USAID Foreign Assistance for Programs Overseas).
What is the central program direction or theme of this APS?
USAID signals a broader direction that extends beyond early-stage research and development. The focus is not only on discovering or refining microbicide candidates, but also on activities required to translate clinical trial outcomes into tools that can be approved, introduced, and used in real-world settings.
How does this APS relate to the CAPRISA 004 clinical trial?
The opportunity builds directly on the CAPRISA 004 clinical trial of 1% tenofovir gel, a landmark study led by South African investigators and jointly supported by USAID and the Government of South Africa.
Why is CAPRISA 004 described as a landmark study in the APS description?
When announced in July 2010, CAPRISA 004 provided the first clear proof that a vaginal microbicide could significantly reduce the risk of HIV infection, shifting the field from asking whether microbicides could work to addressing the practical steps needed for safety, approval, and introduction.
Does the APS focus only on developing new microbicide products?
No. While ongoing research and development for improved and alternative microbicide products remains important, the APS emphasizes work beyond early-stage R&D, including evidence strengthening, regulatory preparation, and practical groundwork for rollout.
What kinds of activities are highlighted as important for moving microbicides toward use?
The APS highlights coordinated work such as additional studies to strengthen the evidence base, preparation of regulatory submissions and supporting documentation, and planning and groundwork for eventual implementation and introduction in developing-country contexts.
What is the award ceiling for this opportunity?
The award ceiling is $168,000,000.
What is the award floor for this opportunity?
The award floor is $0.
What do the ceiling and floor suggest about award size?
The listing suggests a potentially large overall funding amount with flexibility in individual award sizes depending on proposed activities and USAID priorities.
Is cost sharing or matching required?
Yes. Cost sharing or matching is required, meaning applicants would need to contribute some portion of resources, whether in cash or allowable in-kind contributions, consistent with USAID rules and the terms in the full solicitation.
Who is eligible to apply?
Eligibility is described as unrestricted, meaning any type of entity may apply as long as it meets any additional eligibility conditions described in the full announcement.
When was this opportunity posted?
The posting date shown is February 4, 2013.
What was the closing date for applications?
The original and current closing date shown is March 18, 2013.
Is this opportunity still open for applications?
No. The archive date is April 17, 2013, and the dates indicate the opportunity is historical and no longer accepting applications.
Who was the listed point of contact for questions about accessing the full announcement?
The listed point of contact was Kathleen Bumpass, Contracts Specialist.
What phone number was provided for the point of contact?
The phone number provided was 202-567-5008.
Browse more opportunities from the same category: Health
Next opportunity: BOEM FY 2013 Louisiana Coastal Marine Institute
Previous opportunity: Dimensions of Biodiversity
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for APS OAA 13 000001
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (APS OAA 13 000001) also looked into and applied for these:
| Funding Opportunity |
|---|
| Affordable Care Act Health Center Controlled Networks Apply for HRSA 13 267 Funding Number: HRSA 13 267 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Maternal and Child Health (MCH) Nutrition Training Program Apply for HRSA 13 180 Funding Number: HRSA 13 180 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Genomic Centers for Infectious Diseases (U19) Apply for RFA AI 13 009 Funding Number: RFA AI 13 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| MCH Knowledge to Practice Program Apply for HRSA 13 197 Funding Number: HRSA 13 197 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Dental Reimbursement Program Apply for HRSA 13 171 Funding Number: HRSA 13 171 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| MCH Navigator Program Apply for HRSA 13 262 Funding Number: HRSA 13 262 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Grants to Expand the Use of Technology Assisted Care in Targeted Areas of Need Apply for TI 13 008 Funding Number: TI 13 008 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $280,000 |
| High Impact Neuroscience Research Resource Grants (R24) Apply for RFA NS 13 009 Funding Number: RFA NS 13 009 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Innovative and Novel Approaches toward Inner Ear Regenerative Therapies by Early Stage Investigators (R01) Apply for RFA DC 13 002 Funding Number: RFA DC 13 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Improvement of Animal Models for Stem Cell Based Regenerative Medicine (R24) Apply for PAR 13 113 Funding Number: PAR 13 113 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Improvement of Animal Models for Stem Cell Based Regenerative Medicine (R21) Apply for PAR 13 115 Funding Number: PAR 13 115 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Enhancing Opioid Treatment Program Patient Continuity of Care through Data Interoperability Apply for TI 13 010 Funding Number: TI 13 010 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $50,000 |
| NINDS Institutional Center Core Grants to Support Neuroscience Research (P30) Apply for PAR 13 116 Funding Number: PAR 13 116 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| STD Surveillance Network (SSuN) Apply for CDC RFA PS13 1306 Funding Number: CDC RFA PS13 1306 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,100,000 |
| Revision Applications for Research on Assessing the Role of Stigma in HIV Prevention and Care (R34) Apply for RFA MH 14 141 Funding Number: RFA MH 14 141 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Revision Applications for Research on Assessing the Role of Stigma in HIV Prevention and Care (R01) Apply for RFA MH 14 140 Funding Number: RFA MH 14 140 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Electronic Data Methods (EDM) Forum Second Phase (U18) Apply for RFA HS 13 004 Funding Number: RFA HS 13 004 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Rapid Hepatitis C Virus Screening and Referral Apply for TI 13 009 Funding Number: TI 13 009 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $40,000 |
| Offender Reentry Program Apply for TI 13 007 Funding Number: TI 13 007 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $430,000 |
| Rural Health Information Technology (HIT) Workforce Program Apply for HRSA 13 251 Funding Number: HRSA 13 251 Agency: Health Resources and Services Administration Category: Health Funding Amount: $300,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "APS OAA 13 000001", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.